Isomorphic Labs Raises $5B to Push AI Drugs
Isomorphic Labs said on Nov. 17, 2026, it raised $5 billion in a Series C co-led by Greenoaks and Sequoia Capital, six months after a $2.1 billion Series B, to scale its IsoDDE drug design engine and move its first programs toward clinical trials. No valuation was disclosed.
Isomorphic Labs, the London-based AI drug design company spun out of Google DeepMind, said on Nov. 17, 2026, that it has raised $5 billion in an oversubscribed Series C round. Greenoaks and Sequoia Capital co-led the financing, which the company says will help push its first AI-designed drug candidates toward clinical trials.

Key takeaways
- Isomorphic Labs raised $5 billion in a Series C co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor.
- The round comes about six months after a $2.1 billion Series B, bringing the company's announced external funding to about $7.7 billion.
- The company did not disclose a valuation and has not yet put a drug into human trials.
Who invested in the Isomorphic Labs Series C
According to the company's press release, Andreessen Horowitz (a16z) and "several other new investors" joined the round alongside the two lead firms, and Alphabet made what Isomorphic called a "continued significant investment." Every existing outside investor also took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.
Isomorphic did not state a valuation. Bloomberg reported on Nov. 4 that the company was in talks to raise about $5 billion at a valuation of roughly $50 billion; the company has not confirmed that figure.
Isomorphic Labs funding history
The new round is the third and largest since Isomorphic began taking outside money. Adding the three announced rounds together gives about $7.7 billion.
| Date | Round | Amount | Lead |
|---|---|---|---|
| March 31, 2025 | First external round | $600 million | Thrive Capital |
| May 12, 2026 | Series B | $2.1 billion | Thrive Capital |
| Nov. 17, 2026 | Series C | $5 billion | Greenoaks, Sequoia Capital |
What the money is for: IsoDDE and clinical trials
Isomorphic's core product is IsoDDE, its proprietary drug design engine. The company describes it as a suite of foundational simulation AI models that work across multiple therapeutic areas and drug types, paired with in-house AI agents that reason over complex biological systems.
The company said this work is "yielding positive preclinical results" in its internal oncology and immunology programs and with partners, "setting the stage for clinical entry." It lists four uses for the money: maturing IsoDDE, expanding into new biology, building infrastructure for AI-led bioengineering, and building AI-first translational and clinical development capabilities as candidates move toward trials.
"This round enables us to accelerate our progress," founder and CEO Sir Demis Hassabis said in the release, citing work on "driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients."
President Max Jaderberg said, "Every week we are making repeatable scientific advancements enabled by our models." Neil Mehta, founder and managing partner of Greenoaks, called drug development "an optimization challenge of almost infinite scale."
Context: a timeline that has slipped
Isomorphic was founded in 2021 and builds on DeepMind's AlphaFold protein-structure work. It has research deals with Eli Lilly, Novartis and Johnson & Johnson, and runs offices in London, Cambridge, Massachusetts, and Lausanne, Switzerland.
The clinic has been the stated goal for some time. In early 2025, Hassabis said he hoped to have the first AI-designed drug in trials by the end of that year, Sifted reported. That has not yet happened, and the new release still frames clinical entry as the next step rather than giving a date.
The raise is also the first since Google's August reorganization, when Hassabis stepped back from running Google DeepMind day to day and became its chair while continuing to lead Isomorphic.
What's next
The key test is whether Isomorphic's candidates enter human trials and how they perform there. Preclinical results do not guarantee success in patients, and clinical development typically takes years. The company has not said which diseases its lead programs target or when the first trial will start.
FAQ
How much has Isomorphic Labs raised in total?
Its three announced external rounds add up to about $7.7 billion: $600 million in 2025, $2.1 billion in May 2026 and $5 billion in November 2026.
What is Isomorphic Labs' valuation?
The company did not disclose one. Bloomberg reported earlier in November that talks were at about $50 billion.
Does Isomorphic have a drug in clinical trials?
Not yet. The company says its oncology and immunology programs have positive preclinical results and that it is moving its first programs toward clinical trials.
References
- Isomorphic Labs announces Series C investment round — Isomorphic Labs (Nov. 17, 2026)
- Isomorphic Labs announces $5 Billion Series C funding (press release) — Isomorphic Labs (Nov. 17, 2026)
- Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials — TechCrunch (Nov. 17, 2026)
- DeepMind spinout Isomorphic Labs raises $600m from Thrive Capital — Sifted (Mar. 31, 2025)
Editor responsible for AI Newsway. Writes about AI, developer tools, cloud and productivity technology.
Comments 0
Comments are currently disabled.